Cerus Corp. to Release Third Quarter 2019 Results & to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on Octob...
October 21 2019 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today that its third
quarter 2019 results will be released on Wednesday, October 30,
2019, after the close of the stock market. The Company will host a
conference call and webcast at 4:30 P.M. ET that afternoon, during
which management will discuss the Company’s financial results,
provide a general business overview and outlook, and review the
recently published final FDA guidance document on mitigating the
risk of contamination in transfused platelet components.
To listen to the live webcast and view the presentation slides,
please visit the Investor Relations page of the Cerus website at
http://www.cerus.com/ir. Alternatively, you may access the live
conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549
(international).
A replay will be available on the company’s website, or by
dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and
entering conference ID number 2392137. The replay will be available
approximately three hours after the call through November 13,
2019.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System, and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191021005164/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024